News | December 11, 2014

Japanese Study Demonstrates Safety, Efficacy of Hypothermal Pharyngeal Cooling for Cardiac Arrest Patients

Randomized trial indicates reduced incidences of inflammation and blood-clotting disorders


December 11, 2014 — Researchers at Okayama University in collaboration with several medical centers in Japan have demonstrated the safety and efficacy of a hypothermal treatment – pharyngeal cooling – for cardiac arrest patients.

Cooling the brain is known to prevent neurological problems in patients recovering from cardiac arrest. However, most of the current methods for therapeutic hypothermia may not be initiated before return of spontaneous circulation.

Researchers at Okayama University investigated a method for cooling the area at the top of the throat — the pharynx — because the arteries that supply the head with oxygenated blood run nearby. Cooling this area should be a good approach to cooling the brain but so far there have been no complete studies to determine whether pharyngeal cooling could be administered effectively or whether it may lead to other adverse side effects.

The researchers, alongside people working in emergency and critical care clinics, set up a trial for 108 cardiac arrest patients. The medical staff administered treatments with or without pharyngeal cooling to patients at random, and subsequently recorded success rates of resuscitation and physiological conditions, including temperature both at the body core and in the head near the ear (tympanic temperature), mechanical or temperature damage to the pharynx, inflammation and blood platelet levels.

The results of the trial indicated effective cooling of tympanic temperatures, with no observed adverse side effects. In addition, incidences of inflammation and blood-clotting disorders were reduced in patients receiving pharyngeal cooling. As the researchers report, “In conclusion, it appears that the initiation of pharyngeal cooling is safe and feasible before and shortly after recovery of spontaneous circulation in the emergency room.”

For more information: www.okayama-u.ac.jp


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now